

## **Linda M. Pullan, Ph.D.**

**Pullan Consulting**

**www.pullanconsulting.com**

9360 W. Flamingo Road, Suite 110-554, Las Vegas, NV 89147

-----work and cell 805-558-0361 linda@pullanconsulting.com-----

Over 35 years of pharmaceutical and biotech experience. In-depth understanding and proven success in drug development, and evaluation, valuation and negotiation for strategic alliances and licensing deals. Great deal sheet.

### **BUSINESS DEVELOPMENT EXPERIENCE**

#### **Pullan Consulting**

April 2006- present

Working for a variety of small and larger biotech as a business development consultant.

- Representing out-licensing efforts, coordinating out-licensing activities
- Seeking and evaluating opportunities for in-licensing
- Providing preliminary valuations, financial models for deals
- Negotiating and advising on negotiations on buy and sell side (typically 5-10 deals a year signed)
  - Many signed deals (licenses as large as **\$150MM** upfront, options, and university licenses) for Discovery to Phase III
  - Many term sheets always in progress
- Designing partnering presentations
- Advising on strategy and processes
- Leadership recognized:
  - Author of Pullan's Pieces with thousands of confirmed subscriptions
  - Taught negotiations courses, webinars on partnering, presentations on valuations, negotiations, diligence, including EBD Academy master course in negotiations
  - Expert witness in multiple arbitration and court cases on industry deal terms
  - Led panels on oncology licensing, IO, ADCs, Bispecifics, and other science topics
  - Invited Speaker at BIO, Biotech Showcase, BioEurope, BioEurope Spring, BioNetwork etc.
  - Served as interim CEO (Viriome, Inc.)
  - Served on Board of Directors - Aksivi, AUTM Foundation, Viriome, Paloma Pharmaceuticals, IRAD and most recently NLC Health Ventures

#### **Kosan Biosciences, Inc., Hayward, CA**

Oct 2004-March 2006

Vice President, Business Development

- Responsible for all business development activities, strategy, market analysis, financial models, messaging, relationship management and negotiations
- 9 negotiations initiated, 1 subsequently signed (**\$12.5MM** upfront)
- Chair committee for portfolio analysis, long-range planning
- Member of Operating Committee

#### **Amgen Inc., Thousand Oaks, CA**

Director, Oncology and Hematology Licensing

2000-2004

Associate Director, Oncology Licensing

1998-2000

- Created and led licensing team of 10 (including legal and finance) for Amgen's biggest therapeutic areas, oncology and hematology
- Generated 8 major deals and more than 10 others:
  - first clinical deal at Amgen (Ph 3, Praecis, **\$100MM** upfront)
  - Ph 2/3 cancer Ab (Immunomedics, **\$65MM**)
  - acquisition of kinase company Kinetix (**\$170MM**), now Amgen's Boston site

- preclinical Ab (Vanderbilt) – milestones triggered since
- targets and drug development (Tularik, **\$125MM**) – two milestones and acquisition since triggered
- human Ab generation (Abgenix, Medarex, BioSite) – multiple milestones paid
- drug delivery (Skye Pharma)
- companion diagnostics (Dako and Ventana)
- biomarkers (many)
- IP (many)
- Established review process, documents, diligence checklist now in use at Amgen
- Led identification, evaluation, valuation (market forecasts, deal terms and P&L models) and negotiations of technologies & products from targets to market
- Shaped strategy for therapeutic area, licensing, and research
  - Created monthly Therapeutic Area Leadership forum with heads of R, D, Sales and Marketing to drive strategy for all of oncology and hematology
  - Chosen to make presentations and contributions to Research reviews and strategy
  - Created, syndicated and communicated licensing strategy
- Sold value of Amgen for oncology partnering with capabilities pitches, negotiations, mass mailings, oncology licensing brochure, booths at congresses, and numerous speaking invitations

#### **Zeneca Pharmaceuticals, Wilmington, DE**

Collaborations (Licensing) Manager

1995-1998

Research Planning Analyst

1994-1995

- Led identification, evaluation and negotiations of academic and industry research collaborations
  - 4 Significant Deals
  - Established cost/value modeling for external alliances
  - Represented Zeneca at biopartnering conferences (E&Y, H&Q, Connect, Alex Brown)
- Defined neuroscience research, licensing, and hospital business strategies as part of teams
- Wrote Zeneca-wide international bioethics policy and guide
- Represented Zeneca on PhRMA Genomics Key Issues Team
- Continued to drive development strategy for clinical candidates for stroke, pain, other diseases
- Authored position papers on strategic options for senior R&D management

### **RESEARCH EXPERIENCE**

#### **ICI/Zeneca Pharmaceuticals and Monsanto/Searle**

Principal Pharmacologist

1992-1994

Project Leader

1992-1993

Senior Research Pharmacologist

1988-1992

Research Biochemist

1983-1988

- Contributed to promoting 3 drugs into the clinic; 1 now >\$1B sales
- Promoted to lead a team of biologists and chemists (~50 people)
  - Put a glycine antagonist into clinical development for cerebral ischemia (stroke) and pain
  - Contributed in vitro biology on Seroquel; now >\$1B plus antipsychotic on market
  - *In vitro* & *in vivo* biochemistry, receptor binding, second messengers, disease models, behavior
- Represented research team as member Development Strategy Team
- Chaired Zeneca U.S. Safety Committee

### **PUBLICATIONS**

- Produce monthly newsletter (Pullan's Pieces) on science and business for thousands of readers
- Webinars on Deal Prep, Partnering presentations, Valuation, Diligence, Negotiations, What's Hot and What's Not in Oncology Licensing, Non-IO Oncology, ADCs, bispecifics, etc.

- Presented at many invited seminars and panels
- Authored 66 scientific literature publications; Editor of book Neurotherapeutics: Emerging Strategies
- Coauthor with VP of Research on paper on Zeneca's research strategy

## EDUCATION

**PhD**, in Biochemistry, minor in Chemistry, University of California, Riverside, 3.8 GPA

Thesis research on enzyme isolation, kinetics, chemical modification, protein chemistry on the newly discovered carbonic anhydrase III and phosphoglucose isomerase

**BS** in Chemistry, University of Utah, 1978, Magna Cum Laude, 3.8 GPA

## HONORS

- Joined board at NLC Health Ventures
- Moderator for Fireside chat In Silico and Menarini at BioEurope Spring
- BIO.org requested "office hours" for BioInvestor conference
- Moderator for APAC plenary panel, What's Next in Oncology, The deal makers J&J & Nanobiotix
- Expert witness on licensing in litigation (3 cases)
- Taught deal basics for incubator
- Reviewer for Australia's BTB and MRFF program grants
- Strategy review panel for Walter and Eliza Hall Institute
- American University Technology Managers Foundation board member (past)
- Taught (multiple times) master course in negotiation for EBD Academy, diligence course to pharma company
- Webinars and papers chosen by BIO to promote partnering
- Invited speaker for Keck Graduate Institute Advisory Board
- Reviewer for BioCurate incubator proposals
- Reviewer for USC start-up proposals
- Advisor for LARTA for small start-ups
- Lecturer for UCSD, UCSB on entrepreneurship, technology management
- Taught course in Norway for startups
- Taught basics of licensing course for Chinese pharmaceutical company
- Taught due diligence course for public biotech company
- Taught evaluations, valuations and negotiations for Asian company
- UCR College of Sciences Advisory Board
- Special Achievement awards at Amgen for Licensing
- Speaker on impact of new science on drug discovery for Zeneca's annual meeting, as Research Team Leader at SEROQUEL® launch meeting
- Special Achievement Award for coordinating R&D exhibits at Zeneca annual meeting
- Reviewer for Eur. J. Pharmacol.
- Two Zeneca Outstanding Achievement Awards
- Outstanding Teaching Assistant Award and Regents Fellowship from UC system
- Phi Beta Kappa, Phi Kappa Phi, ACS Analytical Chemistry Award

## Deal Sheet

### Strategic Alliances (>\$20MM upfront)

Consulting Client- Big Pharma \$46M upfront plus milestones and royalties, advice and negotiations.

Consulting Client – Big Pharma \$25M upfront, plus milestones and royalties, advice on terms and negotiations.

Consulting Client – Mid size pharma, \$27M upfront plus milestones and royalties, advice on terms and negotiations.

Consulting Client – Big Pharma, \$48.5M upfront, plus milestones and royalties, led negotiations.

Consulting Client – Big Pharma, \$60M upfront, up to \$475M in milestones and royalties. Advice on terms and negotiations.

Consulting Client- Big Pharma, \$40M upfront, \$300M total for preclinical small molecule. Advice on terms and negotiations.

Consulting Client – Biotech, \$40M, company acquisition. Advice on terms and negotiations.

Consulting Client – Chinese pharma, \$220M total for Phase 3. Advice on termsheet and contract.

Consulting Client – Big Pharma, \$27.5M upfront for biologic asset starting Phase 1, did outreach, led negotiations

Consulting Client –Big Pharma, \$150M upfront for Phase 3 asset. Advice on terms and contract.

Consulting Client – Big pharma, \$1B in milestones for 3 molecules. Led negotiations.

Consulting Client – Chinese client, Big pharma, \$56M upfront, \$440M in milestones for 1 molecule, additional terms for other 2 molecules. Led negotiations for one of the biggest deals in China.

Consulting Client – Big pharma, \$100MM upfront cash and equity, Phase 3, negotiations, advice on terms and final contract

Consulting Client – Big Asian Pharma, \$25MM upfront, valuation, advice on negotiations (Phase 3)

Consulting Client – Big pharma, \$25MM upfront, negotiations and advice (pseudo auction, pre-completion of Phase II)

Consulting client – Big Pharma: \$30MM upfront, broad chemistry collaboration; advice and deal structure

Tularik –Amgen: \$125MM, targets and drug development, led evaluation team, launched collaboration that led to acquisition

Praecis – Amgen: \$100MM, Ph 3 GnRH antagonist, led evaluation team

Immunomedics – Amgen: \$65MM, Ph 2/3 NHL Ab, led evaluation team and member of negotiation team

Abgenix – Amgen: multi-antigen Ab creation, supervised evaluator and negotiator

Medarex – Amgen: multi-antigen Ab creation, supervised evaluator and negotiator

Kinetix acquisition by Amgen – \$170MM, kinases and structural biology, led evaluation and diligence

### Mid-Size Deals (>\$10M upfront)

Consulting Client- mid size pharma, discovery collaboration and license, \$27M near term, \$700M in milestones, negotiated.

Consulting Client –Big pharma, \$15M upfront, \$550M in milestones. Introduction and advice thru out negotiations.

Consulting Client – Non-profit, license, negotiation advice (preclinical)

Consulting Client- US Biotech, discovery license, advice.  
Consulting Client – US pharma, discovery license advice.  
Consulting Client – US Biotech, negotiations and advice (Phase II)  
Consulting Client- Regional Pharma, negotiations and advice (Phase II)  
Consulting Client – venture firm, sale of Phase I asset  
Consulting Client – US Biotech, negotiations and advice (Phase 1)  
Consulting Client -- Mid-size pharma, option; led negotiations  
Consulting Client -- Big pharma, discovery collaboration, on negotiation team  
Consulting Client – Major Pharma, advised negotiator (preclinical)  
Vanderbilt – Amgen: preclinical Ab, led negotiation  
Biosite – Amgen: multiple Abs, supervised evaluator and negotiator  
Incyte – Zeneca: genomics database, on negotiation team  
Pharmacopeia – Zeneca: combinatorial chemistry, on negotiation team  
U C Irvine – Zeneca: lead optimization ion channels, led evaluation and negotiations  
U College of London – Zeneca: small molecule lead, led renegotiations

## **Smaller Deals**

Consulting Client – Tech co, advice.  
Consulting Client - China co, advice.  
Consulting Client – China co, advice.  
Consulting Client- Mid size pharma, advice.  
Consulting Client – Big pharma, advice.  
Consulting Client – diagnostic distributor, negotiated.  
Consulting Client – top 10 pharma, option, negotiated.  
Consulting Client- discovery collaboration, advice.  
Consulting Client – discovery collaboration, advice.  
Consulting Client- gene therapy, discovery collaboration, option, negotiated.  
Consulting Client- China biotech, discovery collaboration, negotiated.  
Consulting Client – mid sized pharma, option, negotiated.  
Consulting Client – big pharma, option, negotiated.  
Consulting Client – China biotech, license, negotiated.  
Consulting Client – Big pharma, license, advised.  
Consulting Client- Big Biotech, diagnostic development, advice on negotiations  
Consulting Client- Big pharma, research collaboration, advice on negotiations  
Consulting Client- Australian research institute, research collaboration, led negotiations  
Consulting Client – US Biotech, research collaboration, led negotiations  
Consulting Client- Diagnostics company, license, advice on negotiations  
Consulting Client – university, research collaboration, negotiated  
Consulting Client – EU biosimilars co, license, negotiated  
Consulting Client- US biotech, clinical trial collaboration, advice

Consulting Client – UK biotech, Covid-19 deal, advice

Consulting Client- US biotech, in-licensing bispecific, negotiated

Consulting Client- US biotech, Global pharma pilot study, negotiated

Consulting Client- UK biotech, CRUK clinical trial deal, advised

Consutling Client – Chinese client, Ab generation, terms negotiation

Consulting Client, US biotech, academic in-license, negotiated

Consulting Client- European biotech, platform deal, advised on value and negotiations

Consulting Client- China client biotech, preclinical Ab, advised negotiator

Consulting Client – China client biotech, preclinical bispecific, advised negotiator

Consulting Client- China client biotech, preclinical vaccine, advised negotiator

Consulting Client – US biotech, out-licensing Ab, advised negotiator

Consulting client – China client company, in-licensing from biotech co, led negotiation

Consulting client – China client company, ww rights for University asset, advised negotiator

Consulting Client- computational chemistry collaboration, big pharma, advised negotiator

Consulting Client – chemistry LO and license, \$500M milestones, global pharma, advised negotiator

Consulting Client – small biotech, advised negotiator (preclinical)

Consulting Client- small biotech, advised negotiator (preclinical)

Consulting Client – University, advised negotiator (clinical)

Consulting Client – University, advised negotiator (preclinical)

Consulting Client – small biotech advised negotiator (preclinical)

Consulting Client – Japanese pharma, participated in negotiations

Consulting Client – global pharma, use patent, adviced negotiations

Consulting Client- University, negotiations

Consulting Client – University, negotiations

Consulting Client – Small biotech, JV, participated in negotiations

Consulting Client – small biotech, territorial deal (preclinical), participated in negotiations

Consulting Client – University (clinical), valuation, advice throughout negotiations

Consulting Client – University (platform), led negotiations

Consulting Client- Mid-sized pharma, led negotiations (preclinical)

Consulting Client – Mid-sized pharma, advised negotiations (platform)

Consulting Client – Global pharma, valuations, advised negotiator (preclinical)

Consulting Client – Small biotech, valuations, advised negotiator (preclinical)

Consulting Client – Global pharma, part of negotiations (preclinical)

Consulting Client -- Small biotech, led negotiations (preclinical)

Consulting Client – Small biotech, led negotiations (preclinical)

Consulting Client – University, led in-licensing negotiations (preclinical)

Consulting Client – University, led in-licensing negotiations (preclinical)

Consulting Client- University, led in-licensing negotiations (preclinical)

Consulting Client- small biotech, led in-licensing negotiations (preclinical)

Dako – Amgen: companion diagnostic development, supervised evaluator, led negotiations

Ventana – Amgen: companion diagnostic development, supervised evaluator, led negotiations

Skye Pharma – Amgen: drug delivery, led evaluation and negotiations

Many biomarker deals – supervisory roles

Many IP licenses – negotiator and supervisory roles, some as consultant

## **Webinars and speaking engagements (incomplete)**

Trends in Cross Border Transactions, Bay Helix at BIO 2024 (panelist)

Fireside Chat: In Silico and Menarini, BioEurope Spring 2024 (moderator)

Current State of Asia Pacific region, Biotech Showcase 2024 (moderator)

What's Next in Oncology, BioEurope Spring 2023 (moderator)

Meet the Deal Makers J&J and Nanobiotics, BioEurope Spring 2023 (moderator)

State of Innovation in Asia Pacific at Biotech Showcase 2023 (moderator)

A big pharma view of emerging technologies (organizer and moderator). Sponsored by BIO and Sharevault

Building your pitch at BIO. Sponsored by BIO.

What's hot and what's not in IO 2021? (organizer and moderator) [What's Hot and What's Not in IO 2021 \(sharevault.com\)](#)

What's hot and what's not in oncology licensing? (organizer and moderator) [What's Hot and What's Not in Oncology Licensing in 2020? | ShareVault](#)

What's hot and what's not in antibody drug conjugates? (organizer and moderator) [What's Hot & What's Not in Antibody-Drug Conjugates \(ADC\) Licensing \(sharevault.com\)](#)

Adoptive Cell Therapy: The who, how and when. (organizer and moderator) [WBR67-Adoptive Cell Therapy in Solid Tumors \(sharevault.com\)](#)

Bispecific antibodies: are two really better than one? (organizer and moderator) [Bispecific Antibodies: Are Two Really Better Than One? | ShareVault](#)

Paradigm changing technologies in oncology (organizer and moderator) [Paradigm Changing Technologies in Oncology | ShareVault](#)

China investments and licensing deals (speaker) [China Investments and Licensing Deals - BioProcess InternationalBioProcess International \(bioprocessintl.com\)](#)

LES Pullan's Pieces III: A business development view of the immunology landscape. (speaker) [A Business Development View of the Immunology Landscape | ShareVault](#)

LES Pullan's Pieces II: A business development view of the CNS landscape. (speaker) [A Business Development View of the Central Nervous System Landscape \(sharevault.com\)](#)

LES Pullan's Pieces I: A business development view of the oncology landscape. (speaker) [A Business Development View of the Oncology Landscape | ShareVault](#)

Getting ready for a biopharma partnering deal (speaker) [Getting Ready for a Biopharma Partnering Deal | ShareVault](#)

Nuts and bolts of due diligence in biopharma partnering (speaker) [ShareVault WP Nuts and Bolts of Due Diligence in Biopharma Partnering FINAL11.11.16.pdf](#)

Winning strategies. How to create, grow and sustain a successful life science company (panelist).

<https://www.foley.com/-/media/files/insights/events/pmatch-making-identifying-partners-creative-collab/files/presentation/fileattachment/panel3presentation.pdf>

Anticipating and planning for deal dynamics (interviewed) [https://motionhall.com/blog/callseries\\_planning/](https://motionhall.com/blog/callseries_planning/)

Trends, challenges and opportunities in bispecific antibodies (moderator) BioEurope 2021.

Targeting mRNA: The new frontier of tailored therapeutics (moderator) Demy Colton virtual salon. [VIRTUAL SALON SERIES | Demy-Colton](#)

## Whitepapers

Pullan LM. Successful biotech licensing negotiations [6c5439f0d4b70b0912051404b420ef45 \(wsimg.com\)](#)

Pullan, LM. Valuation of your early drug candidate. A no formulas tour of valuation. [Valuation of Your Early Drug Candidate | ShareVault](#)

Pullan LM. Getting ready for a biopharma partnering deal. [Getting Ready for a Biopharma Partnering Deal | ShareVault](#)

Pullan LM. A business development view of the oncology landscape. [A Business Development View of the Oncology Landscape | ShareVault](#)

Pullan LM, et al., The nuts & bolts of due diligence in biopharma partnering. [The Nuts & Bolts of Due Diligence in Biopharma Partnering | ShareVault](#)

Pullan LM, et al., What's hot and what's not in oncology licensing in 2020? [What's Hot and What's Not in Oncology Licensing in 2020? \(sharevault.com\)](#)

Pullan LM. How to win at the partnering game. [How to Win at the Partnering Game | ShareVault](#)

Pullan LM, et al., What's hot and what's not in immune-oncology. [What's Hot & What's Not in Immuno-Oncology Licensing | ShareVault](#)

Pullan LM, et al., What's the role of non-IO in an IO world. [What's the Role of Non-IO in an IO World? | ShareVault](#)

Pullan LM. Building a better partnering presentation. [Building a Better Partnering Presentation | ShareVault](#)

Pullan LM, et al., What's hot and what's not in antibody-drug conjugate (ADC) licensing. [What's Hot & What's Not in Antibody-Drug Conjugates \(ADC\) Licensing \(sharevault.com\)](#)

## Books and chapters

Pullan LM. "China licensing deals for biologics" in [Advances in Biopharmaceutical Technology in China, 2nd ed.](#) 2018, pp945-959. Bioplan.

Pullan LM and Patel J. editors [Neurotherapeutics: Emerging Strategies](#). 1996. Springer Science.

Pullan LM. Neuroprotective strategies for treatment of acute ischemic stroke. In [Neurotherapeutics: Emerging Strategies](#). 1996. Pp275-322. Springer Science.

## Papers



- Tatlisumak, T et al, A Glycine Site Antagonist, ZD9379, Reduces Number of Spreading Depressions and Infarct Size in Rats With Permanent Middle Cerebral Artery Occlusion. *Stroke* 1998: 190-195.
- Pullan LM. Receptor specific inhibition of N-methyl-D-aspartate stimulated  $^{22}\text{Na}$  flux from rat hippocampal slides by phencyclidine and other drugs. *Neuropharmacology*. 1998 27(5): 493-7.
- Pullan LM. An Efficient Strategy for Optimization of Isocratic Mobile Phase Conditions for HPLC Separation of a Complex Mixture. *Journal of Liquid Chromatography & Related Technologies* 1998: 11. 2697-2708.
- U'Prichard DC and Pullan LM. The future of drug industry research and the Zeneca response. *Research Technology Management; Arlington* Vol. 40, Iss. 6, (Nov/Dec 1997): 35-39.
- Takano, K etl al., Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies. *Stroke* 1997, 28(6): 1255-62.
- Jackson PF et al., Synthesis and Biological Activity of a Series of 4-Aryl Substituted Benz(b)azepines: Antagonists at the Strychnine-Insensitive Glycine Site *Bioorganic & Medicinal Chemistry Letters* 1995, 5(24):3097-3100
- Stauch Slusher, B et al. Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice. *J. Neural Transm. Gen Sect* 1994, 97(3): 175-85.
- Bare TM et al., Synthesis and activity of spiroisindolines as novel noncompetitive NMDA antagonists *Bioorganic & Medicinal Chemistry Letters* 1993: 3(1):55-60
- Zinkand WC et al. Lack of involvement of nitric oxide in NMDA-induced neuronal cell death in cortical culture. *Neuroreport* 1993 18;5(2): 148-50.
- Williams K et al., An antagonist/partial agonist at the polyamine recognition site of the N- methyl-D-aspartate receptor that alters the properties of the glutamate recognition site *Journal of Pharmacology and Experimental Therapeutics* 1992: 262(2):539-44
- Pullan LM et al. Comparison of binding at strychnine-sensitive (inhibitory glycine receptor) and strychnine-insensitive (N-methyl-D-aspartate receptor) glycine binding sites. *Neurosci Lett*. 1992 148(1-2): 199-201.
- Pullan LM et al. Neomycin is an agonist at a polyamine site on the N-methyl-D-aspartate receptor. *J Neurochem*. 1992 59(6): 2087-93.
- Jackson PF et al., Tricyclic quinoxalines as ligands for the strychnine-insensitive glycine site *Bioorganic & Medicinal Chemistry Letters* 1991. 1(12):751-756
- Williams K et al. An antagonist/partial agonist at the polyamine recognition site of the N-methyl-D-aspartate receptor that alters the properties of the glutamate recognition site. *J Pharmacol Exp Ther*. 1992 262(2):539-44.
- Pullan LM et al. Agonist-like character of the (R)-enantiomer of 1-hydroxy-3-amino-pyrrolid-2-one (HA-966). *Eur J Pharmacol*. 1991 208(1): 25-9.
- Pullan LM et al. Spermine reciprocally changes the affinity of NMDA receptor agonists and antagonists. *Eur J Pharmacol* 1991 207(2): 173-4.

- Stumpo, RJ et al. The inhibition of [<sup>125</sup>I]omega-conotoxin GVIA binding to neuronal membranes by neomycin may be mediated by a GTP-binding protein. *Eur J Pharmacol* 1991 206(2): 155-8.
- Pullan LM et al. Stereoselectivity for the (R)-enantiomer of HA-966 (1-hydroxy-3-aminopyrrolidone-2) at the glycine site of the N-methyl-D-aspartate receptor complex. *J. Neurochem* 1990 55(4): 1346-51.
- Jackson PF et al. Tricyclic quinoxalines as ligands for the strychnine-insensitive glycine site. *Bioorganic & Medicinal Chemistry Letters* 1991: 1(12):751-756
- Pullan LM et al., Agonist-like character of the (R)-enantiomer of 1-hydroxy-3-amino-pyrrolid-2-one (HA-966) *European Journal of Pharmacology* 1991 208(1):25-9
- Pullan LM et al., Stereoselective enhancement by (R)-HA-966 of the binding of [<sup>3</sup>H]CPP to the NMDA receptor complex *European Journal of Pharmacology* 1990 189(2-3):237-40
- Pullan LM, et al. The polyamine spermine affects omega-conotoxin binding and function at N-type voltage-sensitive calcium channels. *J Auton Pharmacol.* 1990 Aug;10(4):213-9.
- Pullan LM et al. The polyamine spermine affects omega-conotoxin binding and function at N-type voltage-sensitive calcium channels. *J Auton Pharmacol* 1990 10(4): 213-9.
- Pullan LM. Probing glycine interactions at the N-methyl-D-aspartate receptor with the <sup>22</sup>Na flux assay. 1990 *Amino Acids* (pp.427-435)
- Stumpo RJ et al. Glutamine mimics glycine to enhance [<sup>3</sup>H]TCP binding at the NMDA receptor complex. *Eur J Pharmacol* 1989 170(1-2): 121-2.
- Pullan LM et al. Schild plot analysis of glycine and kynurenic acid at the N-methyl-D-aspartate excitatory amino acid receptor. *Brain Res.* 1989 497(1): 59-63.
- Monahan JB et al., L-[<sup>3</sup>H]Glutamate Binding to an N-Methyl-D-Aspartate Recognition Site in Synaptic Plasma Membranes (1988) In *Neurobiology of Amino Acids, Peptides and Trophic Factors* (pp.235-237)
- Lanthorn TH et al., Alpha- and Beta-Endopsychosins: Physiological Actions and Interactions with Excitatory Amino Acids (1988) in *Neurobiology of Amino Acids, Peptides and Trophic Factors* (pp.181-197)
- Hood W et al., Specific (D, L)-[<sup>3</sup>H]2-Amino-4-Phosphonobutyric Acid Binding to Frozen Synaptic Plasma Membranes (1988) in *Neurobiology of amino acids, peptides and trophic factors*, editors Ferrendelli et al (1988) pp 231-233.
- Pullan LM et al. Excitatory amino acid receptor potency and subclass specificity of sulfur-containing amino acids. (1987) *J Neurochem.* 198 49(4): 1301-7.
- Pullan LM. Automated radioligand receptor binding analysis with templates for Lotus. *Comput Appl Biosc.* 1987 3(2): 131.
- Contreras PC, et al. Phencyclidine. Physiological actions, interactions with excitatory amino acids and endogenous ligands. *Mol Neurobiol.* 1987 Fall;1(3):191-211.

- Pullan LM, Noltmann EA. Purification and properties of pig muscle carbonic anhydrase III. *Biochem Biophys Acta*. 1985 839(2): 147-54.
- Pullan LM, Noltmann EA. Specific arginine modification at the phosphatase site of muscle carbonic anhydrase. *Biochemistry* 1985 24(3): 635-40.
- Pullan LM, Noltmann EA. Simultaneous and independent versus antagonistic inhibition of muscle carbonic anhydrase (CA III) by acetazolamide and cyanate. *Biochem Pharmacol*. 1984 33(16): 2641-5.
- Pullan LM, Noltmann EA. Discovery, characterization, and study of some inhibition properties of two mammalian muscle carbonic anhydrases III. *Ann NY Acad Sci* 1984 429: 152-64.
- Pullan LM et al. Arginine specific modification of rabbit muscle phosphoglucose isomerase: difference in the inactivation by phenylglyoxal and butanedione and in the protection by substrate analogs. *Arch Biochem Biophys* 193 221(2): 489-98.
- Koester MK et al. The p-nitrophenyl phosphatase activity of muscle carbonic anhydrase. *Arch Biochem Biophys*. 1981. 211(2): 632-42.

## **Abstracts**

- Huang, C et al., A chemoproteomic platform for identifying small-molecule modulators of protein-protein interactions, discovering new cancer targets, and revealing previously unknown targets for well-known drugs. *Molecular Cancer Therapeutics* 2021, 20: 12S.

Jackson PF et al., ChemInform Abstract: Synthesis and Biological Activity of a Series of 4Aryl Substituted Benz(b)azepines: Antagonists at the Strychnine-Insensitive Glycine Site April 2010. ChemInform 27(15)

McLaren CD et al., 3-benz[b]azepinyl acrylates as precursors to a variety of potential glycine antagonists. March 1996 ACS National Meeting Book of Abstracts

Payne Gallimore PA et al., 3-amino-2,5-dioxo-1H-benz[b]azepines: Isosteres and prodrugs for 3-hydroxy-2,5-dioxo-1H-benz[b]azepines March 1996 ACS National Meeting Book of Abstracts 211:47-MEDI

Bare TM et al., Synthesis and biological activity of 7-chloro-2-heteroaryl-4-hydroxy-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones with glycine/NMDA antagonist properties March 1996 ACS National Meeting Book of Abstracts

Empfield J et al, 7-chloro-4-hydroxy-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones: Synthetic studies and glycine antagonism of N-2-benzyl and related analogs. March 1996 ACS National Meeting Book of Abstracts

McLaren CD et al., Synthesis of 3,4-fused-furano-, 3,4-fused-pyrido-, and 3,4-fused-pyrrolo-1H-benz[b]azepines. March 1996 ACS National Meeting Book of Abstracts

Forst J. et al., 2-alkyl-7-chloro-4-hydroxy-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline -1,10-diones: Glycine site antagonism of the NMDA receptor and in vivo functional activity. March 1996 ACS National Meeting Book of Abstracts

Empfield J et al., 2-alkyl-7-chloro-4-hydroxy-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline -1,10-diones: Glycine site antagonism of the NMDA receptor and in vivo functional activity. March 1996 ACS National Meeting Book of Abstracts

Davenport, TW et al., Synthesis and activity of a series of pyridazinoquinolines, pyridazinobenzthiazines, and pyridazinoindoles; Antagonists at the strychnine-insensitive glycine receptor site March 1996 ACS National Meeting Book of Abstracts

Bare TM et al., Syntheses and structure activity relationships of 1-hydroxy-3,4,5,10-tetrahydropyridazino[4,5-b]quinoline-4,10-diones: Antagonists at the glycine site of the NMDA receptor. March 1996 ACS National Meeting Book of Abstracts

Warwick PJ et al, Electronic control of N vs O alkylation during the enantioselective synthesis of HA-966. March 1996 ACS National Meeting Book of Abstracts

Bare TM et al, 2-aryl pyridazinoquinolinediones: Novel glycine site NMDA antagonists with potent in vitro and in vivo properties. March 1996 ACS National Meeting Book of Abstracts

Bare TM et al., Pyridazino[4,5-b]quinolinediones: Novel potent glycine site NMDA antagonists showing neuroprotectant activity in stroke models. March 1996 ACS National Meeting Book of Abstracts

Chapdelaine, MJ et al., Glycine site antagonists of the NMDA receptor complex: 3-hydroxy-2,5-dioxo-1H-benz[b]azepines. March 1996 ACS National Meeting Book of Abstracts

**Newsletters** (11 issues per year since 4/2006)

Incomplete Public archive. [Email Newsletter Archives by Robly - Pullan Consulting](#)